The publication summarizes multiple areas of focus:
- Myocardial Injury measured by multiple myocardial and inflammatory markers increases mortality risk – Higher enzyme values = higher mortality.
- Myocardial markers which stabilized or declined were associated with a lower mortality risk consistent with the importance of aggressive management.
- Patients with elevated cardiac markers (e.g. Troponin T) and a history of CV disease had nearly twice the mortality risk (69.4%) compared to patients with elevated cardiac markers but no history of CV disease (37.5%).